New hope for hard-to-treat lung cancer: combo therapy enters late-stage trial
NCT ID NCT05020769
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 30 times
Summary
This study tests a new drug combination (SI-B001 plus osimertinib) in people with advanced non-small cell lung cancer that has stopped responding to standard treatments. About 14 adults with specific genetic mutations will receive the combo to see if it shrinks tumors and how safe it is. The goal is to control the disease, not cure it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Sun Yat-sen University Cancer Center (SYSUCC)
Guangdong, Guangzhou, 510075, China
-
The Second Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
-
The Second Affiliated Hospital of Guilin Medical University
Guilin, Guangxi, China
Conditions
Explore the condition pages connected to this study.